Tetrahidropiridotienopirimidina compounds and their use for treating cell proliferative disorders.

A compound of formula (I) ** (See formula) ** in Burnout is 0, 1 or 2; n is 0, 1, 2 or 3; q is 0 or 1; R1 represents H, alkyl (C1-C4) or halo; R2 is selected from the group consisting of H, -CN, halo, (C1-C4), -O (C1-C4) alkyl, (C2-C4) and alkynyl (C2-C4); R3 is selected from the group consisting of H, halo, -CN, (C1-C4), ethynyl, propargyl, and * -O (CH2) pAr, wherein p is 0, 1 or 2 and Ar represents phenyl, pyridyl, thiazolyl, thiophenyl, or pyrazinyl and wherein Ar optionally bears 1 or 2 substituents selected from the group consisting of (C1-C4) halo; or R2 and R3 may be joined, and taken together with the carbon atoms to which they are attached form a saturated condensed carbocyclic or unsaturated five or six members or form a fused heterocycle in which R2 R3 combined group and represent by formula ** (See formula) ** where each Ar 'and Ar' represents phenyl, pyridyl, thiazolyl, thienyl, or pyrazinyl and wherein each Ar 'and Ar' 'optionally having 1 or 2 substituents selected from the group consisting of (C1-C4) halo; R4 is selected from the group consisting of H, -CN, (C1-C4), -O (C1-C4), halo, (C2-C4) and alkynyl (C2-C4); R5 represents H or halo; when n is 0, R7 is H; when n is 1, 2 or 3, R7 represents H; I hydroxyl; -NR12R13 wherein R12 represents H or (C1-C6) optionally having 1 or 2 hydroxyl groups or mono- or di- ((C1-C4) -alkyl) amino; and R13 represents H, alkyl (C1-C6) alkyl or (C3-C6) alkyl optionally bearing said cycloalkyl groups and 1 or 2 hydroxyl or mono- or di- ((C1-C4) -alkyl) amino; ** (See formula) ** in which R14 is hydroxyl, (C1-C4) alkoxy (C1-C4) or mono- or di- ((C1-C4) -alkyl) amino, optionally bearing turn each alkyl substituent a hydroxyl substituent; ** (See formula) ** optionally bearing 1 or 2 hydroxyl, (C1-C4) alkoxy (C1-C4) or mono- or di- ((C1-C4) -alkyl) amino, optionally bearing his once each alkyl substituent a hydroxyl substituent; and wherein r is 0, 1 or 2; ** (See formula) ** optionally having 1 or 2 substituents (C1-C4), optionally bearing alkyl turn each substituent a hydroxyl substituent; and wherein X represents O, S (O) NR15 so, where s is 0, 1 or 2; and R15 represents (C1-C4); ** (See formula) ** or when n = 2, R7 and R9 may be joined, and taken together with the carbon atoms to which they are attached and the carbon atoms involved, form a ring structure ** (See formula) ** wherein R16 represents (C1-C4); R8 represents halo, hydroxy or (C1-C4); R9 represents H or -CH2-Y, wherein Y is mono- or di- ((C1-C4) -alkyl) amino, or ** (See formula) ** R10 represents H; or R9 and R10 may be taken together to form a bond, resulting in an acetylenic linkage; or a pharmaceutically acceptable salt thereof.